Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 12, 2001, Pages 2032-2038

  Davis Jr , Harry R ^a   Compton, Douglas S ^a   Hoos, Lizbeth ^a   Tetzloff, Glen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherosclerosis; Cholesterol absorption; Ezetimibe; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN E; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035572836     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq1201.100260     Document Type: Article

References (38)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Prevention Study Group
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
5. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)(3S)-hydroxypropyl]-(4S)-(4- hydroxyphenyl)-2-azetidinone (SCH58235): A designed, potent, orally active inhibitor of cholesterol absorption
6. In vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH58235) through the identification of the active metabolites of SCH48461
7. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption
8. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
9. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
10. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs
11. The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis
12. Apolipoprotein E and atherosclerosis
13. The value of apolipoprotein E knockout mice for studying the effects of dietary fat and cholesterol on atherogenesis
14. Mouse models of atherosclerosis
15. Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models
16. ApoE-deficient mice develop lesions of all phases on atherosclerosis throughout the arterial tree
17. Use of gene-manipulated models to study the physiology of lipid transport
18. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH48461
19. Enzymatic determination of total serum cholesterol
20. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
21. A simple method for isolation and purification of total lipids from animal tissues
22. The effect of acyl CoA: Cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine
23. Advanced atherosclerotic lesions in the innominate artery of apoE knockout mice
24. Elevated levels of chylomicron- and VLDL-remnants leads to atherosclerosis in apoE transgenic mice
25. Apoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse
26. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins
27. Atherosclerosis as a post-prandial disease
28. Postprandial lipoprotein metabolism and atherosclerosis
29. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart study
30. High-density lipoprotein: The clinical implications of recent studies
31. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
32. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
33. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters
34. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
35. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin
36. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol
37. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin
38. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin